Mobile

A Phase IIa, Double-blind, Randomised, Placebo-Controlled Dose Escalation Study to Evalulate the Safety, Tolerability, Pharmacokinetics and Activity of GS-9450, a Caspase Inhibitor, in Subjects with C...

Update Il y a 4 ans
Reference: EUCTR2007-001601-16

A Phase IIa, Double-blind, Randomised, Placebo-Controlled Dose Escalation Study to Evalulate the Safety, Tolerability, Pharmacokinetics and Activity of GS-9450, a Caspase Inhibitor, in Subjects with Chronic Hepatitis C

Woman and Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

• To investigate the safety and tolerability of multiple oral doses of GS-9450 in subjects with chronic hepatitis C (HCV).

Inclusion criteria

  • Chronic hepatitis C

Links